Joshua Reed has served as a member of our board of directors since March 2021. Mr. Reed is currently Chief Financial Officer of Omega Therapeutics, a role he has served in since 2022. From 2018 to 2022, he held the role of Chief Financial Officer of Aldeyra Therapeutics. From 2006 to 2018, he held roles of increasing responsibility at Bristol-Myers Squibb (BMS), including mostly recently Vice President and Head of Finance Operations for the company’s United States and Puerto Rico operations. Prior to BMS, Mr. Reed served as Vice President, Strategic Business Development at JPMorgan Chase and worked in investment banking at Credit Suisse First Boston. Mr. Reed received a B.S. in Finance from Rutgers University and an MBA from the University of Michigan’s Ross School of Business.
